Octaplas LG® Powder for solution for infusion: Making a Vital Contribution to the Health of Canadian Soldiers

02/14/2024
Press release

TORONTO, ON – February 1, 2024 – Octapharma Canada Inc is proud to announce the provision of Octaplas LG® Powder for solution for infusion to the Canadian Armed Forces under Health Canada's regulatory framework for Public or Canadian Armed Forces Health Emergencies. This innovative product, a lyophilized plasma solution, is specifically designed for use in managing trauma in battlefield scenarios.

 Trauma, particularly uncontrolled hemorrhage, is a leading cause of death among soldiers in combat. Octaplas LG® Powder for solution for infusion addresses this critical need, offering a rapid and effective response to life-threatening bleeding. This freeze-dried plasma solution is easily transported and quickly reconstituted, making it ideal for use in the challenging conditions of a battlefield.

 The Canadian Armed Forces' decision to secure Octaplas LG® Powder for solution for infusion demonstrates remarkable leadership and commitment to the health and safety of its members. This pioneering step, the first of its kind globally, underlines the Forces' dedication to adopting innovative medical treatments to enhance soldier care in challenging environments.

 While Octaplas LG® Powder for solution for infusion is not licensed for sale in Canada, this initiative reflects Octapharma's dedication to medical innovation and our commitment to supporting the Canadian Armed Forces in their vital mission.

 Octapharma is dedicated to improving the lives of patients worldwide. By providing Octaplas LG® Powder for solution for infusion to the Canadian Armed Forces, we are honoring this commitment, ensuring our soldiers have access to life-saving medical care when they need it most.

About Octapharma: Octapharma specializes in the development and production of human proteins from human plasma and cell lines. Committed to patient care and medical innovation, Octapharma products have been enhancing the health and well-being of patients around the world.

Media Contact

Sri Adapa

+1 (416) 531-5533  

info.canada@octapharma.com

Critical Care